Creative Planning
MDGL icon

Creative Planning’s Madrigal Pharmaceuticals MDGL Stock Holding History

Creative Planning’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-400
Closed -$3.56K – 3132
2024
Q1 		$3.56K Buy
+400
New +$94.2K ﹤0.01% 2895

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Creative Planning's MDGL Position: Q2 2026 in Review

Creative Planning increased its Madrigal Pharmaceuticals (MDGL) stake by 9.5% in Q2 2026, buying an estimated $585K and bringing the position to 13,147 shares worth $7.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Creative Planning first reported a position in MDGL in Q3 2013 and has held it in 28 quarters since. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Creative Planning held 13,147 shares of Madrigal Pharmaceuticals worth $7.06M as of Q2 2026.
  • Creative Planning bought 1,142 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $585K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1140 holding.
  • Creative Planning first reported a position in Madrigal Pharmaceuticals in Q3 2013 and has held it in 28 quarters since.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.